Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants (PNIRS in VLBWI)
Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants: a Pilot Study
This study will look at whether a monitoring method called near-infrared spectroscopy (NIRS), can help assess lung disease in premature babies.
The main aim of this study is to describe lung oxygen levels measured by NIRS in premature babies with respiratory distress syndrome (RDS) during the first 72 hours after birth. The study will include babies born at or before 32 weeks of pregnancy who need continuous positive airway pressure (CPAP) for RDS. The study will also assess whether these lung oxygen measurements can help predict which babies will need surfactant treatment, and whether they can predict which babies may need more than one dose of surfactant.
The study will also compare lung NIRS measurements with other ways of assessing breathing problems, including lung ultrasound scores and oxygen-related measurements. In addition, the researchers will compare lung oxygen measurements with brain oxygen measurements. They will also look at whether surfactant treatment changes oxygen levels in the lungs and brain. Information from routine vital signs, such as heart rate, breathing rate, and oxygen saturation, will also be studied to see whether these measurements can help predict the need for surfactant.
Added to this researchers will look at the hemodynamics of surfactant administration by seeing how the heart and blood vessels react to surfactant administration
調査の概要
詳細な説明
Aim: To determine pulmonary regional oxygen saturation (prSO2) in preterm infants (≤32 weeks) with respiratory distress syndrome (RDS) requiring continuous positive airway pressure (CPAP) with or without surfactant replacement therapy (SRT)
Objectives:
Primary: Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life. Secondary: (1) Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS, (2) Evaluate the ability of prSO2 to predict the need for repeat surfactant administration in preterm infants with RDS, (3) Determine correlation between prSO2, lung ultrasound (LUS) scores and oxygenation indices.
Tertiary: (1) Determine the correlation between prSO2 and cerebral oxygenation (crSO2), (2) Determine the effect of surfactant administration on prSO2 and crSO2, (3) longitudinal analyses of vital signs (HR, SpO2, NIRS, oxygenation indices) to predict SRT, (4) determine the hemodynamic effects of SRT (longitudinal correlation of NIRS, haemodynamic parameters)
This will be an investigator-initiated, prospective, observational trial.
Preterm infants born at a gestational age ≤ 32 weeks will be recruited from a single neonatal center, Tygerberg Hospital, Cape Town, South Africa.
All preterm infants ≤ 32 weeks and/ or ≤1800g will be eligible for enrollment
Study Procedures
Recruitment and enrollment processes Infants will be screened within the first 3 hours after birth. Infants meeting enrollment criteria will be placed on study monitoring devices upon arrival in the neonatal unit, if meeting eligibility criteria.
Randomization/ blinding No randomization will occur in this study. Blinding is not possible due to visible monitoring equipment. Treating clinicians will however be directed not to use the monitors for any decision-making regarding patient management.
Monitoring Devices
-
Near-infrared spectroscopy will be performed using INVOS 5100c (Medtronics, Minneapolis, MN, USA) with 2 transducers, will be used that allows monitoring of 4 regions of interest. In this study 3 regional saturations will be monitored - pulmonary (left and right) and cerebral
- Pulmonary NIRS - Pulmonary sensors will be placed in a horizontal position at the 4th intercostal space area (nipple line) on the left and right hemithorax
- Cerebral NIRS - Cerebral sensor will be placed on the right of the forehead
-
Vital sign monitoring: Synchronized vital signs (heart rate (HR), respiratory rate (RR), peripheral oxygen saturation (SpO2) (Nellcor) will be monitored using a multi-parameter monitor (Mindray UMEC15, Shenzhen, China).
-
Non-invasive cardiac output monitoring: Haemodynamic monitoring will occur using the ICON Core from Osypka Medical. This provides non-invasive monitoring of numerous haemodynamic parameters, including cardiac output, stroke volume, systemic vascular resistance, cardiac contractility and thoracic fluid content. ICON sensors will be placed in standard positions on the forehead, neck arm and leg for monitoring.
Intervention procedures
1. Ultrasound:
- Lung ultrasound (LUS) will be performed after placement of the NIRS (within the first 6 hours of life) and daily. LUS will also be performed prior to any SRT. alculated. Video-clips will be stored and reviewed by blinded co-investigators.
- Cranial ultrasound (CUS) will be performed on day 1,2 and 3 to monitor for any intraventricular haemorrhage as well as to measure cerebral blood flow velocities, which may affect crSO2 values.
- Point-of-care echocardiography (POC-echo) will be performed to determine cardiac function, cardiac output, and the presence of a patent ductus arteriosus, size, flow velocity and pattern, which may affect prSO2 and crSO2 values. Standard echocardiography techniques will be used and will be performed daily on day 1,2 and 3 of life.
Trial duration
The trial will start enrolling 1 November 2026 or when all procedures have been completed. Trial will be completed when 100 participants have been recruited.
Discontinuation of study intervention
Monitoring of the infant will stop, and sensors will be removed if:
- Requested by mother
- Requested by treating clinician
- Thoracic intervention required (e.g. intercostal drainage for pneumothorax)
- Surgery required (e.g. laparotomy for focal intestinal perforation)
- Sensors interfere with medical management
Withdrawal from study
At any time point the mother or treating clinician may request withdrawal of the infant from the study, for any reason, whether for personal choice (by the mother), safety considerations or administrative reasons. Monitoring of the infant will be stopped immediately, and no further data will be collected. However, the infant will remain in the study for data analyses and outcome and clinical measure collection, unless the mother specifically requests that their infant's data not be included. Withdrawal of the infant from the study, irrespective of reason, will not influence the continued management of the infant and they will continue to receive management as per protocols in the institution.
Duration of study participation
Study participation for each infant is:
- Initiated within the first 3 hours of life
- Monitoring until 72 hours after birth
- Follow up from 72 hours until final discharge from hospital or in-hospital death.
Infants who are transferred to other institutions will be followed up for length of stay as well as neonatal respiratory complications (length of respiratory support, bronchopulmonary dysplasia, death)
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Lizelle Van Wyk, PhD
- 電話番号:+27219389506
- メール:lizelle@sun.ac.za
研究場所
-
-
-
Cape Town、南アフリカ、7530
- 募集
- Tygerberg Hospital
-
コンタクト:
- Lizelle Van Wyk, PhD
- 電話番号:6058 +27219384911
- メール:lizelle@sun.ac.za
-
コンタクト:
- Pierre Goussard, PhD
- 電話番号:+27219389506
- メール:pgouss@sun.ac.za
-
主任研究者:
- Lizelle Van Wyk, PhD
-
副調査官:
- Pierre Goussard, PhD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
All preterm infants 27-32 weeks born at Tygerberg Hospital, Cape Town, South Africa will be elligible for enrollment
説明
Inclusion Criteria:
- Preterm infant ≤ 32 weeks gestational age and/ or birth weight ≤ 1800g
- Infant diagnosed with respiratory distress syndrome requiring CPAP after birth
- Infant born at the research institution
Exclusion Criteria:
- Infants ≤ 26 weeks gestational age or <750g
- Infants with other causes of respiratory distress
- Infants with antenatal or postnatally diagnosed structural pulmonary abnormalities
- Infants with known or suspected chromosomal abnormalities
- Infants with other congenital structural abnormalities that may require surgery in the first 72 hours after birth
- Infants with known or suspected congenital infections including congenital syphilis, cytomegalovirus or toxoplasmosis
- Infants intubated after birth or requiring intubation and invasive ventilation immediately after birth
- Infants with a 5-minute Apgar ≤ 5
- Instillation of surfactant prior to enrollment
- Infants not expected to survive the first 72 hours after birth
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
CPAP only
Infants receiving CPAP only |
Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position |
|
SRT
Infants receiving CPAP plus surfactant |
Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PRSO2 values
時間枠:72 hours
|
Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life |
72 hours
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
SRT prediction
時間枠:72 hours
|
Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS |
72 hours
|
|
Compare prSo2 & lung ultrasound between groups
時間枠:72 hours
|
Determine correlation between prSO2 and lung ultrasound (LUS) scores between groups |
72 hours
|
|
Compare prSo2 & OSI between groups
時間枠:72 hours
|
Determine correlation between prSO2 and OSI between groups |
72 hours
|
|
Compare prSo2 & SOPI between groups
時間枠:72hrs
|
Determine correlation between prSO2 and SOPI between groups |
72hrs
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PRSO2/CUS
時間枠:72hours
|
Determine the correlation between prSO2 and cerebral oxygenation (crSO2) between groups |
72hours
|
|
Longitudinal analysis SOPI
時間枠:72 hours
|
longitudinal comparison of SOPI between groups |
72 hours
|
|
Longitudinal OSI
時間枠:72 hours
|
longitudinal comparison of OSI between groups |
72 hours
|
|
Longitudinal thoracic fluid content (TFC)
時間枠:72 hours
|
longitudinal comparison of TFC between groups |
72 hours
|
|
Longitudinal CI
時間枠:72 hours
|
longitudinal comparison of cardiac index between groups |
72 hours
|
協力者と研究者
協力者
出版物と役立つリンク
一般刊行物
- Dani C, Miselli F, Zini T, Scarponi D, Luzzati M, Sarcina D, Fusco M, Dianori F, Berardi A. Measurement of lung oxygenation by near-infrared spectroscopy in preterm infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 2024 Jun;59(6):1631-1637. doi: 10.1002/ppul.26955. Epub 2024 Mar 5.
- Ozdemir FE, Alan S, Aliefendioglu D. The diagnostic value of pulmonary near-infrared spectroscopy in the early distinction of neonatal pneumonia from transient tachypnea of the newborn. Pediatr Pulmonol. 2023 Nov;58(11):3271-3278. doi: 10.1002/ppul.26656. Epub 2023 Aug 30.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 32886
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Patient data, as per SUN HREC guidelines, can only be shared upon an agreed upon data sharing agreement
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。